Clinical trials: sponsored by Chipscreen Biosciences, Ltd.
T2DM (Type 2 Diabetes Mellitus)
Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets
This trial includes two parts: a food effect (FE) study and a multiple-dose pharmacokinetic (PK) study. The FE study is a randomized, open-label, two-period, two-sequence crossover study designed to evaluate the effect of a…
- Trial name
- NCT07511010
- Testing
- Chiglitazar/Metformin extended-release tablets under fasting conditions, Chiglitazar/Metformin extended-release tablets after a high-fat meal, multiple-dose of Chiglitazar/Metformin extended-release tablets
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
T2DM (Type 2 Diabetes Mellitus)
Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets
This is a pilot bioequivalence study. It is a randomized, open-label, single-dose, crossover study. The primary objective of this study is to preliminarily evaluate the pharmacokinetic parameters and their variability of the test…
- Trial name
- NCT07412015
- Testing
- treatment T (dose 1), treatment T (dose 2), treatment R (dose 1)
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
T2DM (Type 2 Diabetes Mellitus)
Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets
This is a single-center, randomized, open-label, two-period, two-sequence crossover bioequivalence study under fed conditions. The primary objective is to evaluate the bioequivalence of a single oral dose of the test formulation…
- Trial name
- NCT07519265
- Testing
- Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1, Chiglitazar tablet, dose 1, Metformin extended-release tablet, dose 1
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Healthy
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules
The study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CS32582 after single or multiple oral administration, as well as the food effect on the pharmacokinetics in healthy subjects.
- Trial name
- NCT06224595
- Testing
- CS32582 capsule
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Hepatic Impairment
Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function
This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with varying degrees of hepatic impairment…
- Trial name
- NCT05515445
- Testing
- Chiglitazar
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Renal Impairment
Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function
This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with renal impairment compared to subjects with…
- Trial name
- NCT05515458
- Testing
- Chiglitazar
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Healthy
A Clinical Trial of CS12192 in Healthy Subjects
The study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CS12192 after single or multiple oral administration, as well as the food effect on the pharmacokinetics in healthy subjects.
- Trial name
- NCT05922709
- Testing
- CS12192 capsule
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
T2DM
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
This Phase 1 open label study is being conducted to characterize the pharmacokinetic (PK) and safety profiles of Chiglitazar with Empagliflozin，Atorvastatin and Valsartan in healthy subjects.
- Trial name
- NCT05681273
- Testing
- Chiglitazar, Empagliflozin, Atorvastatin
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Healthy Volunteers
Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers
The purpose of this study is to further study the pharmacokinetic characteristics of Chiauranib Capsule in Healthy Volunteers with High Fat Diet.
- Trial name
- NCT05346601
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.